Macular Degeneration Association Issues Urgent Supplement Warning for Patients

ByConnor Hodde

The Macular Degeneration Association, a nonprofit dedicated to preventing blindness, today issued an urgent warning to patients suffering from a form of the disease known as “intermediate dry age-related macular degeneration.”  MDA leaders and ophthalmologists are advising patients to talk with their doctors about a proven and commonly prescribed vitamin supplement containing zinc, an ingredient that might actually be harmful in some cases.

Read the entire article here.

Similar Posts

A bionic prosthetic eye that speaks the language of your brain

ByConnor Hodde

Sheila Nirenberg of Cornell University has been trying to work out how the retina in your eye communicates with your brain — and judging by a recent talk at TEDMED, it seems like she’s actually cracked it. Nirenberg produced mathematical equations that, with startling accuracy, encode images into neuron pulses that can be understood by an…

Biodegradable nanoparticles slip through mucus

ByConnor Hodde

Researchers at Johns Hopkins University (JHU) have created biodegradable, ultra tiny, nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The interdisciplinary team of researchers, led by Justin Hanes of the JHU Center for Nanomedicine, developed the nanoparticles so that they not only penetrate…

‘Positive Stress’ Helps Protect Eye from Glaucoma

ByConnor Hodde

Researchers increased the resistance of  cells to damage by repeatedly exposing the mice to low levels of oxygen similar to those found at high altitudes. The stress of the intermittent low-oxygen environment induces a protective response called tolerance that makes nerve cells — including those in the eye — less vulnerable to harm. Stress is…

Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics

ByConnor Hodde

Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics.  “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic.  We intend on dosing our first patients for A1AT deficiency by the end of this year…

First Human Test of Optogenetics Could Restore Sight to the Blind

ByConnor Hodde

Before our brains build a visual image of our world, a chain of cells in our eyes must convert light into electrical signals that are processed in the brain. Photoreceptor cells in the retina represent the first link in this chain, and they are reactive to photons, or the fundamental particle of visible light. Retinitis pigmentosa causes these cells to…